@article{article, title  = {{Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).}},

 publisher = {{Elsevier}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/140820 https://doi.org/10.1016/j.jbo.2018.09.008 }},

 year = {{2018}},

 month = {{11}},

 author = {{Coleman RE and Collinson M and Gregory W and Marshall H and Bell R and Dodwell D and Keane M and Gil M and Barrett-Lee P and Ritchie D and Bowman A et al}},

 doi = {{10.1016/j.jbo.2018.09.008}},

 volume = {{13}},

 journal = {{JOURNAL OF BONE ONCOLOGY}},

 pages = {{123-135}},

 note = {{Accessed on 2025/12/05}}}